CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Olsson, Eleonor ^a   Honeth, Gabriella ^a,c   Bendahl, Pär Ola ^a   Saal, Lao H ^a   Gruvberger Saal, Sofia ^a   Ringnér, Markus ^a   Vallon Christersson, Johan ^a   Jönsson, Göran ^a   Holm, Karolina ^a   Lövgren, Kristina ^a   Fernö, Mårten ^a   Grabau, Dorthe ^b   Borg, Åke ^a   Hegardt, Cecilia ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD24 ANTIGEN; CD44S ANTIGEN; CD44V ANTIGEN; CD44V2-V10 ANTIGEN; CD44V3-V10 ANTIGEN; CD44V8-V10 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ISOPROTEIN; MESSENGER RNA; TUMOR MARKER;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CANCER SURVIVAL; CLUSTER ANALYSIS; CONTROLLED STUDY; EXON; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; BREAST TUMOR; CLASSIFICATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASTIC STEM CELLS; PROTEIN ISOFORMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 80053174609     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-418     Document Type: Article

References (35)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
5. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
6. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Badve S, Nakshatri H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8(5):R59. 10.1186/bcr1610, 1779499, 17062128.
7. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777-1785. 10.1093/jnci/djj495, 17179479.
8. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100(9):672-679. 10.1093/jnci/djn123, 18445819.
9. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007, 356(3):217-226. 10.1056/NEJMoa063994, 17229949.
10. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10(3):R53. 10.1186/bcr2108, 2481503, 18559090.
11. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006, 66(21):10233-10237. 10.1158/0008-5472.CAN-06-1464, 17079438.
12. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4(1):33-45. 10.1038/nrm1004, 12511867.
13. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010, 46(7):1271-1277. 10.1016/j.ejca.2010.02.024, 20303742.
14. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 2005, 11(9):3309-3314. 10.1158/1078-0432.CCR-04-2184, 15867228.
15. Foekens JA, Dall P, Klijn JG, Skroch-Angel P, Claassen CJ, Look MP, Ponta H, Van Putten WL, Herrlich P, Henzen-Logmans SC. Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 1999, 84(3):209-215. 10.1002/(SICI)1097-0215(19990621)84:3<209::AID-IJC2>3.0.CO;2-9, 10371335.
16. Johannsson OT, Staff S, Vallon-Christersson J, Kytola S, Gudjonsson T, Rennstam K, Hedenfalk IA, Adeyinka A, Kjellen E, Wennerberg J, et al. Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. Lab Invest 2003, 83(3):387-396.
17. Ackland ML, Michalczyk A, Whitehead RH. PMC42, a novel model for the differentiated human breast. Exp Cell Res 2001, 263(1):14-22. 10.1006/excr.2000.5106, 11161701.
18. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17(10):1253-1270. 10.1101/gad.1061803, 196056, 12756227.
19. Ferno M, Stal O, Baldetorp B, Hatschek T, Kallstrom AC, Malmstrom P, Nordenskjold B, Ryden S. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 2000, 59(1):69-76. 10.1023/A:1006332423620, 10752681.
20. Ryden L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K, Kallstrom AC, Landberg G, Stal O, Thorstenson S, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005, 41(2):256-264. 10.1016/j.ejca.2004.06.030, 15661551.
21. Baldetorp B, Bendahl PO, Ferno M, Alanen K, Delle U, Falkmer U, Hansson-Aggesjo B, Hockenstrom T, Lindgren A, Mossberg L, et al. Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates. Cytometry 1995, 22(2):115-127. 10.1002/cyto.990220207, 7587742.
22. Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 2008, 109(2):255-262. 10.1007/s10549-007-9645-1, 17636398.
23. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007, 9(1):R16. 10.1186/bcr1649, 1851391, 17263897.
24. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65(7):2554-2559. 10.1158/0008-5472-CAN-04-3913, 15805248.
25. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007, 13(7):1987-1994. 10.1158/1078-0432.CCR-06-1823, 17404078.
26. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007, 104(18):7564-7569. 10.1073/pnas.0702507104, 1855070, 17452630.
27. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010, 12(3):R42. 10.1186/bcr2596, 2917037, 20576095.
28. Vallon-Christersson J, Nordborg N, Svensson M, Hakkinen J. BASE--2nd generation software for microarray data management and analysis. BMC Bioinformatics 2009, 10:330. 10.1186/1471-2105-10-330, 2768720, 19822003.
29. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, Quackenbush J. TM4 microarray software suite. Methods Enzymol 2006, 411:134-193.
30. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
32. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality?. Nat Med 2009, 15(9):1010-1012. 10.1038/nm0909-1010, 19734877.
33. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer 2011, 11(4):254-267. 10.1038/nrc3023, 21390059.
34. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011,
35. Klingbeil P, Natrajan R, Everitt G, Vatcheva R, Marchio C, Palacios J, Buerger H, Reis-Filho JS, Isacke CM. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast cancer research and treatment 2010, 120(1):95-109. 10.1007/s10549-009-0380-7, 19350388.